中文名稱:MK 1439 | 英文名稱:MK 1439 |
CAS:1338225-97-0 | 有效期: 一年 |
產(chǎn)地: 濟(jì)南 | 保存條件: -20℃儲存 |
純度規(guī)格: 98% |
Doravirine是一種新型的非核苷的HIV- 1逆轉(zhuǎn)錄酶抑制劑.
Doravirine is a novel non-nucleoside inhibitor of HIV-1 reverse transcriptase with potent activity against wild-type virus (95% inhibitory concentration 19 nM, 50% human serum).
target:HIV [1]
In vitro: Doravirine exhibits potent antiviral activity against wild-type virus and K103N, Y181C, and K103N/Y181C mutant viruses, with IC50 value of 12, 21, 31, and 33 nM, respectively. [1] MK-1439 exhibited similar antiviral activities against 10 different HIV-1 subtype viruses (a total of 93 viruses).[2]
In vivo: Administration of 50 mg doravirine with a high-fat meal is associated with slight elevations in AUC time zero to infinity (AUC0-∞) and C24 h with no change in Cmax. Midazolam AUC0-∞ is slightly reduced by coadministration of doravirine (geometric mean ratio 0.82, 90% CI 0.70, 0.97). [3]
成立日期 | 2017-05-16 (8年) | 注冊資本 | 500000 |
員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 中間體,有機(jī)合成試劑,分子砌塊,原料藥,有機(jī)合成藥 | 經(jīng)營模式 | 工廠,試劑,定制 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報(bào)價日期 | |
---|---|---|---|---|
詢價 |
VIP9年
|
滄州恩科醫(yī)藥科技有限公司
|
2024-12-23 | |
¥427 |
VIP3年
|
TargetMol中國(陶術(shù)生物)
|
2024-12-12 | |
¥840 |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2024-12-11 | |
¥2883.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 | |
詢價 |
濟(jì)南澳森醫(yī)藥科技開發(fā)有限公司
|
2019-11-21 |